Clinical Trial Update: Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating decitabine in patients with chronic-phase chronic myeloid leukemia refractory to imatinib mesylate (Gleevec).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED